Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12051877rdf:typepubmed:Citationlld:pubmed
pubmed-article:12051877lifeskim:mentionsumls-concept:C0302592lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C0679729lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C1518578lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C0549379lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C0020823lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C0144576lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:12051877lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:12051877pubmed:issue3lld:pubmed
pubmed-article:12051877pubmed:dateCreated2002-6-7lld:pubmed
pubmed-article:12051877pubmed:abstractTextIfosfamide, paclitaxel, and cisplatin have moderate single-agent activity in patients with metastatic or recurrent cancer of the uterine cervix. We administered a combination of these three agents to a large number of patients with metastatic or recurrent cervical cancer to evaluate its activity.lld:pubmed
pubmed-article:12051877pubmed:languageenglld:pubmed
pubmed-article:12051877pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12051877pubmed:citationSubsetIMlld:pubmed
pubmed-article:12051877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12051877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12051877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12051877pubmed:statusMEDLINElld:pubmed
pubmed-article:12051877pubmed:monthJunlld:pubmed
pubmed-article:12051877pubmed:issn0090-8258lld:pubmed
pubmed-article:12051877pubmed:authorpubmed-author:DimopoulosMel...lld:pubmed
pubmed-article:12051877pubmed:authorpubmed-author:GikaDimitraDlld:pubmed
pubmed-article:12051877pubmed:authorpubmed-author:EfstathiouEle...lld:pubmed
pubmed-article:12051877pubmed:authorpubmed-author:Papadimitriou...lld:pubmed
pubmed-article:12051877pubmed:authorpubmed-author:SarrisKyrillo...lld:pubmed
pubmed-article:12051877pubmed:authorpubmed-author:AravantinosGe...lld:pubmed
pubmed-article:12051877pubmed:authorpubmed-author:KalofonosChar...lld:pubmed
pubmed-article:12051877pubmed:authorpubmed-author:GourgoulisGeo...lld:pubmed
pubmed-article:12051877pubmed:authorpubmed-author:SkarlosDimost...lld:pubmed
pubmed-article:12051877pubmed:authorpubmed-author:BafaloukosDim...lld:pubmed
pubmed-article:12051877pubmed:issnTypePrintlld:pubmed
pubmed-article:12051877pubmed:volume85lld:pubmed
pubmed-article:12051877pubmed:ownerNLMlld:pubmed
pubmed-article:12051877pubmed:authorsCompleteYlld:pubmed
pubmed-article:12051877pubmed:pagination476-82lld:pubmed
pubmed-article:12051877pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:meshHeadingpubmed-meshheading:12051877...lld:pubmed
pubmed-article:12051877pubmed:year2002lld:pubmed
pubmed-article:12051877pubmed:articleTitleCombination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.lld:pubmed
pubmed-article:12051877pubmed:affiliationDepartment of Clinical Therapeutics and Radiotherapy, Alexandra Hospital, Athens, Greece. mdimop@med.uoa.grlld:pubmed
pubmed-article:12051877pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12051877pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12051877pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:12051877pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed